Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
ALISO VIEJO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a late-stage biopharmaceutical company, today announced that the first patients have been randomized in two registrational...
-
ALISO VIEJO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a late-stage biopharmaceutical company, today announced the appointment of Jean-Frédéric Viret, Ph.D., as the company’s Chief...
-
First-in-Human (FIH) Trial at 36 Months: 37% reduction in mean intraocular pressure (IOP) in evaluable patients across all dose groups with 95% of patients off all topical IOP-lowering drops100% of...
-
42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001)100% of patients were off all topical IOP-lowering medications at 24 months100% of treated patients achieved 20/30 or...
-
ALISO VIEJO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a late-stage biopharmaceutical company, today announced the appointment of Anand Sundaram as the company’s Vice President,...
-
ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O’Farrell to its...
-
Financing supports SpyGlass Pharma’s platform through the readout of two Phase III pivotal trials ALISO VIEJO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a privately held ophthalmic...
-
All patients achieved 20/30 or better best corrected distance visual acuity (BCDVA)Significant IOP reduction at 18 months was also demonstrated with 100% of patients off all topical IOP-lowering...
-
Dr. Pujara brings extensive industry experience to guide late-stage development of the SpyGlass Drug Delivery Platform ALISO VIEJO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a...
-
Dublin, March 07, 2025 (GLOBE NEWSWIRE) -- The "Ocular Hypertension - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.The "Ocular Hypertension - Pipeline...